MedTrace Logo

REal World Data in LYmphoma and Survival in Adults

NCT03869619 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2021-06-28

No results posted yet for this study

Summary

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.

REALYSA is a platform perfectly set up to

* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)…
* Document treatment effectiveness in real life and observance
* Address socio-economical questions

Conditions

  • Diffuse Large B Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Marginal Zone Lymphoma (MZL)
  • T-cell Lymphoma (T-NHL)
  • Hodgkin's Lymphoma (HL)
  • Burkitt Lymphoma (BL))

Interventions

OTHER

Real-life epidemiological platform of lymphoma in France

The REALYSA database will be described with the following characteristics: * Number of patients included per month in total and according to subtype of lymphoma * Number of patients in each region in total and according to subtype of lymphoma

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    collaborator OTHER

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Hervé Ghesquières, MD · Hospices Civils de Lyon

  • Alain Monnereau, MD · Université de Bordeaux : Inserm

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-14
Primary Completion
2027-11-14
Completion
2027-11-14

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03869619 on ClinicalTrials.gov